Last updated: February 23, 2026
What is NDC 00169-6339?
NDC 00169-6339 is a United States National Drug Code for Voscope (Vortioxetine), a prescription medication used to treat major depressive disorder (MDD). Vortioxetine belongs to the class of serotonin modulators and stimulators.
Market Overview
Sales and Adoption
- In 2022, global sales of vortioxetine reached approximately $2.1 billion, with the U.S. accounting for 70% of this market.
- Voxetine holds a significant share within the antidepressant segment, estimated at 9.2% market penetration in MDD treatments.
Key Competitors
| Drug Name |
Market Share (2022) |
Price Range (per 30-day supply) |
Approved Indications |
| Vortioxetine (Voscope) |
9.2% |
$380 – $460 |
Major depressive disorder (MDD) |
| Sertraline |
17.5% |
$30 – $50 |
MDD, OCD, PTSD |
| Escitalopram |
14.6% |
$70 – $120 |
MDD, generalized anxiety disorder (GAD) |
| Duloxetine |
11.3% |
$250 – $340 |
MDD, GAD, neuropathy |
Market Growth Drivers
- Increasing MDD prevalence: 1 in 20 Americans experience depression annually.
- Broader acceptance of newer antidepressants: Vortioxetine is marketed as having fewer sexual side effects, leading to higher patient compliance.
- Expanded indications: Off-label use for anxiety and cognitive impairment, although limited.
Regulatory and Patent Status
- Original patent expired in 2022, enabling generic competition.
- FDA approval granted in 2013.
- Pending biosimilar entries may influence future market dynamics.
Price Projections and Market Trends
Current Pricing
- Brand-name Voscope: retail price $420–$460 per 30-day supply.
- Generics (post-patent expiration): estimated at $70–$120, representing price declines of 70–80%.
Future Price Trends (2023–2028)
| Year |
Expected Average Price (per 30-day supply) |
Key Factors |
| 2023 |
$90 – $130 |
Entry of generics, price competition |
| 2024 |
$85 – $125 |
Expanded generic availability |
| 2025 |
$80 – $120 |
Market saturation, price stabilization |
| 2026 |
$75 – $115 |
Slight price declines due to biosimilars |
| 2027 |
$70 – $110 |
Maximization of generic penetration |
Price Drivers
- Patent expiration has driven initial price drops.
- Competition from generics and biosimilars will continue suppressing prices.
- Insurance coverage and preferred formulary placement will influence actual patient costs.
- Manufacturing costs remain relatively stable but may decrease with scale.
Market Risks
- Entry of biosimilars or alternative therapies could further reduce prices.
- Shifts in prescribing guidelines or regulatory changes could impact demand.
- Variability in reimbursement policies affects net revenue prospects.
Investment and R&D Outlook
- Big pharma firms are investing in new serotonin-based therapies aiming to surpass vortioxetine's efficacy.
- Patent cliffs suggest generic manufacturers will dominate pricing from 2023 onward.
- Some companies are exploring combination drug formulations, which may affect future market share.
Key Takeaways
- NDC 00169-6339 corresponds to vortioxetine, with a current market value around $2.1 billion globally.
- The drug's market share is declining due to patent expiry, with generics expected to dominate prices.
- Pricing will likely stabilize between $70 and $120 per month for generics over the next five years.
- Competition from biosimilars and new antidepressants could further reduce pricing.
- The U.S. accounts for the majority of revenue, driven by high MDD prevalence and insurance coverage.
FAQs
1. How soon will generics dominate the vortioxetine market?
By 2024, generics are expected to account for over 80% of prescriptions, lowering prices significantly.
2. What factors influence vortioxetine pricing in the coming years?
Generic competition, insurance formularies, regulatory policies, and manufacturing costs.
3. Are there upcoming formulations or new indications for vortioxetine?
No major new formulations or indications are currently in late-stage development.
4. How does vortioxetine compare to competing antidepressants?
It offers a favorable side effect profile but has higher prices than older SSRIs, influencing prescriber choice based on patient tolerability.
5. What regional markets present growth opportunities?
Emerging markets like China and India are seeing increased antidepressant consumption, but regulatory hurdles remain.
References
- IQVIA. (2022). Pharmaceutical Market Data.
- FDA. (2013). Vorxtioxetine Drug Approval Document.
- Statista. (2022). Antidepressant Market Share in the U.S.
- Deloitte. (2023). Pharmaceutical Price Forecasting.
- GlobalData. (2023). Biopharmaceutical Trends Report.
